Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Baghpat Bypass Crossing, Delhi-Haridwar Highway, NH-58, Meerut, UP, India.
Eur Rev Med Pharmacol Sci. 2012 May;16(5):667-71.
Hepatitis C virus (HCV) infection is widespread, abhorrently under-diagnosed, and radically under-treated. Globally, infection with HCV is a major cause of acute hepatitis and chronic liver disease. Therefore, novel HCV inhibitors are required for the treatment of the HCV infected patients.
This review gives the detailed knowledge of upcoming therapy such as NS5B polymerase inhibitors that are urgently needed.
In the past decade, intensive hard work has focused on the discovery of both structural and nonstructural inhibitors of the HCV NS5B polymerase. These demanding efforts have resulted in various promising agents advancing in clinical development with emphasis on clinical efficacy and impact for future combination studies.
丙型肝炎病毒（HCV）感染广泛存在，令人憎恶的是，其诊断不足且治疗严重不足。在全球范围内，HCV 感染是急性肝炎和慢性肝病的主要原因。因此，需要新型 HCV 抑制剂来治疗 HCV 感染患者。
本综述详细介绍了急需的新型治疗方法，如 NS5B 聚合酶抑制剂。
在过去十年中，人们集中精力深入研究 HCV NS5B 聚合酶的结构和非结构抑制剂的发现。这些艰巨的努力取得了各种有前途的候选药物的进展，这些候选药物在临床开发中强调了临床疗效和对未来联合研究的影响。
